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Abstract
Background: It is generally agreed that diffusion of botulinum toxin occurs, but the extent of the spread and its clinical importance are disputed. Many factors
have been suggested to play a role but which have the most clinical relevance is a subject of much discussion.
Methods: This review discusses the variables affecting diffusion, including protein composition and molecular size as well as injection factors (e.g., volume, dose,
injection method). It also discusses data on diffusion from comparative studies in animal models and human clinical trials that illustrate differences between the
available botulinum toxin products (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB).
Results: Neither molecular weight nor the presence of complexing proteins appears to affect diffusion; however, injection volume, concentration, and dose all play
roles and are modifiable. Both animal and human studies show that botulinum toxin products are not interchangeable, and that some products are associated with
greater diffusion and higher rates of diffusion-related adverse events than others.
Discussion: Each of the botulinum toxins is a unique pharmacologic entity. A working knowledge of the different serotypes is essential to avoid unwanted
diffusion-related adverse events. In addition, clinicians should be aware that the factors influencing diffusion may range from properties intrinsic to the drug to
accurate muscle selection as well as dilution, volume, and dose injected.
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Introduction
Botulinum toxin (BoNT) preparations act by binding presynaptically
to high-affinity recognition sites on the cholinergic nerve terminals and
decreasing the release of acetylcholine, causing a neuromuscular
blocking effect. This inhibition of acetylcholine release leads to muscle
weakness and the potential for the relief of undesirable muscle
contraction, hence serving as an effective treatment for a wide range of
muscle disorders including strabismus, blepharospasm, hemifacial
spasm, cervical dystonia, and spasticity.1
There are seven serologically distinct types of BoNT, designated A
through G, which are antigenically and serologically distinct but
structurally similar. All have similar neurotoxic properties resulting in
flaccid muscle paralysis; however, only the A (onabotulinumtoxinA
[ONAA], abobotulinumtoxinA [ABOA], and incobotulinumtoxinA
[INCOA]) and B (rimabotulinumtoxinB [RIMAB]) forms have been
approved for clinical use. Each botulinum product is purified and
manufactured using proprietary processes, resulting in unique agents
that differ in such features as molecular weight, uniformity of toxin
complex size, protein content, and the presence of inactive ingredients,
all of which can impact performance characteristics including potency,
duration of effect, and adverse event (AE), and diffusion or migration
profile.
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The AEs associated with BoNT are generally of three types: those
due to expected effects of the neurotoxin (e.g., excessive local muscle
weakness), those due to diffusion of the neurotoxin to nearby,
uninjected muscles, and those resulting from systemic distribution of
the toxin.2 Diffusion of BoNT beyond the target muscle is of clinical
concern because of the potential for local and systemic effects that
result in muscle weakening away from the desired site. BoNT may
diffuse across fascial planes to adjacent muscles or be spread
hematogenously.3 At its extreme, the possible leakage of BoNT into
the systemic circulation may manifest as clinical botulism4,5 leading to
respiratory failure and death.6
Methods
In this review, published data on the variables affecting diffusion,
including those pertaining to protein composition and molecular size
of a given botulinum toxin and also factors such as injection volume
and dose, and injection method (e.g., needle gauge used, speed of
injection, and target muscle localization), are discussed. In addition,
findings on diffusion from comparative studies in animal models and
human clinical trials that illustrate differences between available,
approved botulinum toxin products are elucidated. While this is not a
systematic review, a prespecified protocol was followed for the
literature search. Potentially relevant publications were obtained from
a PubMed search conducted during October of 2010 by Linne´a Elliott
and Maria Vinall of The Curry Rockefeller Group under the direction
of the authors. The search focused on English language publications
with the terms botulinum toxin, botulinum neurotoxin, and diffusion
or migration. The results of this search were reviewed by the authors,
who added additional publications they considered noteworthy but
which were not identified by the search. Published abstracts from
recent medical conferences in relevant fields were also searched, and
pertinent abstracts from those were included in the review. The final
choice of references was made by the authors.
Results and discussion
The diffusion characteristics of BoNT have been well studied in
humans7–10 and animals11,12 using a variety of techniques, including
compound muscle action potentials (CMAPs) and motor-evoked
potentials,7 histological determination of glycogen-depleted muscles,13
acetylcholine esterase staining,14 muscle fiber diameter variability,15
and quantitative electromyography (EMG) measures of muscle
activity.16
Evidence for diffusion comes from both animal and human studies.
In a study using muscle biopsy to identify spread, Borodic et al.15
reported a diffusion gradient of BoNT/A over a distance of 30–45 mm
from the point of injection into latissimus dorsi muscle of rabbits.14
The extent of denervation gradient or diffusion was dose dependent.
Another study used neural cell adhesion molecule (N-CAM) staining to
assess the diffusion of activity of equipotent doses of three BoNT/A
formulations from the point of injection along the mouse hind limb.
The results showed a similar time course of paralysis, and minimal but
comparable diffusion in the anatomical area adjacent to the site of
injection that decreased over time in a similar manner.17 Results of an
electrophysiologic study in patients with blepharospasm and facial
hemispasm treated for the first time with BoNT/A in the orbicularis
oculi muscle showed a significant effect in untreated muscles with
different peripheral innervation that could not be explained by axonal
diffusion from the terminal nerve endings of the facial nerve and which
the investigators concluded was related to local diffusion of the BoNT/
A.7 A study that investigated whether the volume of solution used to
inject equivalent units of botulinum exotoxin A affects the diffusion of
toxin and areas of rhytid diminution in the treatment of dynamic
forehead lines found that injection of botulinum exotoxin A in low
concentration and higher volume resulted in greater diffusion and a
larger affected area. The pattern of toxin spread was altered by
muscular contraction in the injected sites.10
Although most clinicians agree that diffusion of BoNT occurs, its
extent and clinical importance has been disputed. In a study of patients
receiving BoNT to treat hemifacial spasm, Lorenzano and colleagues18
assessed the nearby untreated muscles of patients, both clinically and
neurophysiologically, and concluded that diffusion did not occur to
any significant extent. This finding was echoed by Carli and
colleagues,17,19 who reported that intramuscular injections of BoNT/
A to the tibialis anterior muscle of mice exhibited only limited diffusion
to adjacent muscles. In another animal study using radio-labeled
BoNT and autoradiography, Tang-Liu and colleagues20 showed no
detectable systemic effects or generalized botulinum neurotoxin
toxicity, indicating that most of the toxin remained at the injection site.
Pickett et al.21 has suggested that the confusion regarding the extent
and clinical relevance of diffusion among the different botulinum
toxins can be attributed to incorrect extrapolations of information
obtained from animal studies to clinical settings, the inappropriate
testing of products with different dose ratios, the incorrect suggestion
that products with larger complex molecular size migrate less, and, in
some cases, poor study design.
Depending on the clinical indication for which it is used, diffusion of
BoNT may be advantageous. Clinicians may capitalize on effects of
diffusion when giving injections for palmar and axillary hyperhidro-
sis.22,23 When treating larger muscles with BoNT, most often seen in
patients with spasticity, many investigators now recommend trying to
increase the diffusion characteristics of the toxin by using high-dilution
volumes.24
Variables that may affect diffusion
It has been suggested that diffusion of BoNT is influenced by a
number of factors such as dose, concentration, volume, rate of
injection, needle size, distance of needle tip from the neuromuscular
junction, number of injections, target muscle selection, the presence of
muscular fascia, the presence of tissue damage at the injection site,
muscle contraction following injection, and the protein composition
and molecular size of the BoNT formulation.2,10,11,25,26 However,
dose, concentration, and volume are probably the greatest contribu-
tors, in that the greater the dose, concentration, or volume, the greater
the risk of diffusion (Table 1).10,15,27
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Protein composition and molecular size
Based on the principle that larger proteins diffuse more slowly
through an identical aqueous medium than smaller proteins, Foster
and colleagues2 predicted that a BoNT of greater size or molecular
weight would be less likely to diffuse outside the target tissue than those
of smaller size. Thus, ONAA would be less likely to diffuse outside the
target tissue than ABOA, RIMAB, or INCOA. However, Carli and
colleagues17 found the diffusion characteristics of the three products to
be indistinguishable. In addition, in a long-term clinical study,28 the
diffusion profile of ONAA and INCOA (which is free of complexing
proteins) did not differ, suggesting that the complexing proteins are
neither necessary for BoNT’s therapeutic effect nor relevant for tissue
diffusion. This is consistent with earlier findings that the 150-kDa
neurotoxin molecule is released from the 900-kDa complex in less than
a minute when exposed to physiological pH values.29 There is also no
difference between purified neurotoxin alone or toxin complex in
terms of localization at the site of injection or subsequent migration
into body tissues.20 Other studies have also reported that smaller size
or the absence of complexing plays no role in toxin diffusion,30,31 and
that INCOA has an in vivo diffusion profile comparable with that of
preparations retaining the complexing proteins.1,32
Injection factors
Diffusion of botulinum toxin may be dose dependent, and specific
complications may be related to the choice of injection site. In a
retrospective analysis of 26 patients with adult onset idiopathic
spasmodic torticollis treated with BoNT/A for a mean of 1.1 years,
Borodic et al.14 noted that treatment with a median of 150 IU of
ONAA resulted in a significantly (p50.026) higher incidence of
dysphagia than a median dose of 100 IU when the treatment was
administered via the sternomastoid muscle but not when the posterior
cervical muscle group was injected alone. When the investigators
conducted a prospective study in the same patient population and
limited the dose at the sternomastoid muscle to 100 IU, they noted a
substantial decrease in the incidence of dysphagia.14 Participants in a
study evaluating the safety and efficacy of two doses of ONAA (50
units and 100 units) in the treatment of essential hand tremor reported
hand weakness that was dose dependent (30% of participants in the
low-dose group and almost 70% in the high-dose group).33 Injection
site was not identified as a contributing factor in this study.
Injection volume has also been implicated as a factor in diffusion. In
one study, a fivefold increase in volume resulted in an ,50% increase
in affected area.10 In another study, the diffusion gradient around the
site of injection increased with the concentration of BoNT injected.15
At BoNT/A doses of 5–10 IU, a gradient of denervation occurred
throughout the entire muscle with no apparent endpoint, suggesting
that both the magnitude of denervation and the extent of the gradient
are dose dependent. A possible consequence of greater volume leading
to more diffusion into surrounding tissue may be diminution in
duration and magnitude of effect.10
It is most likely that both dose and volume are important
determinants of the effects on the target muscle. Results of a dose-
ranging, electroneurographic study investigating the dose equivalence,
diffusion characteristics, and safety of ABOA and ONAA in 79
volunteers showed significant and similar reductions in compound
muscle action potential amplitude in the extensor digitorum brevis 2
weeks after injection, with effects persisting to the 12-week time point.
For both products, the reduction in amplitude increased with
increasing doses and with increasing concentration.27
Other injection-related factors that may influence diffusion but to a
lesser extent include needle gauge and speed of injection, since too
large a gauge needle and/or too fast an injection could lead to trauma
to the target tissue with the result that toxin uptake in the target area is
decreased, leaving more toxin to spread to adjacent areas.26 Spread
can also be influenced by the distance between the tip of the needle
and the neuromuscular junction (NMJ), with uptake being enhanced
and spread reduced when the needle tip is close to a cluster of
NMJs.26,34 Rosales and colleagues11 have suggested that muscle
architecture (e.g., whether and how the individual muscle units are
arranged in compartments) may also influence the spread of BoNT.
Limiting diffusion
Perhaps the most useful technique to limit diffusion is target muscle
localization. Several techniques using EMG and endoscopic or
imaging guidance are purported to increase the accuracy of targeting
and thus reduce diffusion. Use of EMG, electrical stimulation (ES), or
ultrasound guidance is employed in children for difficult-to-locate
individual muscle groups.26 EMG is also commonly used to confirm
appropriate localization of the injection needle in specific muscles
immediately before injection. Molloy and colleagues35 examined the
accuracy of muscle localization in patients with focal hand dystonia
without EMG guidance and found that only 37% of needle placement
attempts reached the target muscles or muscle fascicles, demonstrating
the need for EMG guidance for correct localization of desired muscles.
In contrast, superficial, easily targeted muscles can be injected directly,
without a need for special techniques.36
Geenen and colleagues37 studied 12 patients who received BoNT for
focal hand dystonia: eight patients under passive EMG guidance and
four with ES. Although the limited study concluded that ES was at
least as good as EMG monitoring, both injection techniques resulted in
Table 1. Factors Thought to Affect Diffusion
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weakness of non-targeted muscles. EMG guidance may be used with
(active) or without (passive) ES. Passive EMG guidance can be used for
the treatment of cervical and laryngeal dystonia, as well as strabismus.
Active EMG guidance may be applied when treating writers’,
musicians’, and typists’ cramps, spasticity, and other conditions where
it is difficult to accurately target the muscle using voluntary
contraction. EMG guidance may allow more precise injections and
the identification and treatment of deep cervical muscles, and, indeed,
the magnitude of improvement in cervical dystonia may be greater
with EMG guidance.38
Ultrasound is a relatively convenient, painless, and less time-
consuming procedure. Sconfienza and colleagues39 have reported that
the use of ultrasound to guide needle positioning prior to injecting
BoNT into the iliopsoas muscle in 10 patients with spinal lesions
allowed for easy and exact needle placement. The use of ultrasound
guidance has also been shown to produce results that are superior to
manually guided injections in the treatment of sialorrhea in patients
with Parkinson’s disease.38
Comparative studies
For each of the botulinum toxins the volume, dose, and accuracy of
the toxin placement appear to have the most effect on the clinical
outcome.
Animal studies of diffusion
The diffusion profiles of BoNT/A and BoNT/B products have been
studied in numerous animal studies. In one study, equipotent doses of
ONAA, ABOA, and INCOA caused a similar duration of paralysis
with no difference in diffusion when injected into the tibialis anterior
muscle of mice.17 However, in two other studies in which ONAA,
ABOA, and RIMAB were injected into the gastrocnemius muscle of
mice, ONAA displayed less diffusion than either ABOA or
RIMAB.40,41 Different results were seen in a study that examined
the effect of ONAA and RIMAB injected into the abductor pollicis
brevis muscle of juvenile monkeys. In that study, the authors noted
dose-dependent diffusion into both nearby and relatively remote
muscles with ONAA but not RIMAB.11 The results from these studies
confirm that some BoNT products are clearly not interchangeable and
indicate that, at clinically effective doses, side-effect rates may be
different.2
Human clinical trials suggesting diffusion differences
ABOA versus ONAA. In a crossover study in which 212 patients with
blepharospasm were randomized to receive double-blind ONAA or
ABOA (ONAA/ABOA ratio of 1:4 IU), ABOA was associated with a
significantly (p,0.05) greater incidence of AEs than ONAA,
specifically ptosis (three cases with ONAA versus 14 cases with
ABOA; p,0.01). The authors hypothesized that the reason for the
difference in AEs might be related to the diffusion profile of the two
products.42 Results from a double-blind, randomized, three-period,
crossover study involving 54 patients with cervical dystonia indicated
that ABOA (ONAA/ABOA ratios of 1:3 and 1:4) is more efficient than
ONAA for both impairment and pain in cervical dystonia; however,
the number of AEs was higher with both ABOA treatments. The most
frequent AE was dysphagia, found in 3%, 15.6%, and 17.3% (ONAA,
ABOA 1:3, and 1:4, respectively) of the patients.43 The study results,
reported by Ranoux and colleagues,43 differed from the only other
study to compare the conversion factor between ONAA and ABOA
units for the treatment of cervical dystonia44 in several respects. The
earlier study was a parallel design, while the study by Ranoux and
colleagues used a crossover design that allowed patients to serve as
their own control, thus eliminating some of the individual differences
that might contribute to an AE (e.g., a thin neck). In addition, in the
study by Ranoux and colleagues, a standardized protocol for injections
was used and the same volume was injected for each of the three
treatments. In light of these controls, the authors suggested that the
higher AE profile of ABOA may in some way be related to its efficacy
and its greater tendency to diffuse within the tissues.43
In a review of clinical and preclinical studies evaluating the diffusion
properties of ONAA, ABOA, and RIMAB, de Alemeida and
colleagues25 concluded that higher doses of ABOA are needed to
achieve efficacy similar to ONAA and that these higher doses are
associated with an increase in diffusion-related AEs. The authors
suggested ONAA has the least potential for diffusion, followed by
ABOA, then RIMAB. These results are in accord with prior studies
noting a lack of dose equivalence between ONAA and ABOA.
Sampaio and colleagues45 noted that 3–5 units of ABOA is required to
achieve the same therapeutic or aesthetic effect as 1 unit of ONAA.
Lowe and colleagues46 have suggested that when doses are titrated to
provide similar efficacy, the result is a ratio of ED50 (e.g., effective dose
for 50% of the population receiving drug) values of approximately 1:5
(ONAA:ABOA), noting that at this ratio ONAA has a lower risk of
diffusion than ABOA.
INCOA versus ONAA versus ABOA). INCOA and ONAA have been
found to have comparable efficacy and safety in large phase 3 clinical
trials in blepharospasm47 and cervical dystonia.48 According to
Frevert,49 the similar AE profiles seen in these studies are indicative
of similar diffusion profiles. In a phase 1B study in 32 healthy
volunteers, after injection of INCOA or ONAA into the extensor
digitorum brevis muscle, CMAP analysis of two adjacent muscles
(abductor hallucis and abductor digiti quinti) revealed no reduction of
the muscle activity caused by diffusion after injection of either toxin.1
After intramuscular injection into the forehead, the diffusion profiles
of INCOA and ONAA were not significantly different, while ABOA
produced a significantly greater area of diffusion versus INCOA at
comparable doses and identical volumes of injection.50,51
RIMAB versus ONAA. In a small study that investigated the diffusion
of ONAA relative to RIMAB, RIMAB consistently produced a greater
radius of toxin diffusion, as measured by the wrinkle reduction area,
calculated using a digital micrometer on traced scanned images.9
Other, larger studies also suggest that RIMAB diffuses differently from
the other botulinum toxins. In a multicenter, randomized, double-
blind, parallel-arm study comparing ONAA and RIMAB for
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treatment of cervical dystonia, both dysphagia and dry mouth were
more frequent with RIMAB. Dysphagia was reported by 48% of
subjects treated with RIMAB versus 19% treated with ONAA
(p50.0005); 80% of subjects treated with RIMAB reported dry mouth
compared with 41% of ONAA-treated subjects (p50.0001).52 In
another report, mild (but not moderate/severe) dry mouth was also
significantly (p50.0005) more frequent with RIMAB than with
ONAA.53 A systematic review and analysis of the published literature
comparing rates of dysphagia and dry mouth showed clear differences
with RIMAB. Among the 70 published articles included in the
analysis, RIMAB had the highest number that reported an association
with rates ranging from 3.2% to 90%.54 This would suggest that
RIMAB has the highest local and systemic diffusion properties
compared with the other toxins.
Conclusions
It is generally accepted that containment of BoNT diffusion is a
desirable goal after injection. An accumulating body of evidence
suggests that some of the botulinum agents have different diffusion
characteristics. Meticulous placement of the toxin using correct dosing
exactly targeted to the right muscle to produce a precise treatment
effect offers the best chance of a good outcome. Techniques such as
EMG guidance can also help to control the effects of diffusion by
increasing the accuracy of the injection.35,55,56
Although BoNT serotypes are structurally and functionally similar,
specific differences in neuronal acceptor binding sites, intracellular
enzymatic sites, and species sensitivities suggest that each serotype is its
own unique pharmacologic entity, sometimes due to distinct purifica-
tion and manufacturing procedures. Physicians must have a working
knowledge of the different serotypes, different doses used for each
formulation of each serotype, and the side-effect profile of each
product in order to insure against diffusion-related AEs. One should
also be aware that a number of factors influence comparative data on
efficacy, diffusion, and spread. These factors may range from
properties intrinsic to the drug to accurate muscle selection and to
the dilution, volume, and doses injected. In particular, the results of the
clinical trials must be considered within the context that there are still
no data on the conversion rate among the various treatments. Thus,
too high or too low concentrations may have been used in the
individual studies, making it difficult to draw too firm a conclusion
from any one trial.
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